Much of the data on the benefit of bivalirudin in reducing the risk of bleeding are derived from randomized trials among patients with STEMI 6 or from studies in which bivalirudin was compared with UFH plus GPI. [7] [8] [9] It is not known, however, whether the bleeding reduction with bivalirudin seen in these settings can be extrapolated to lower risk cohorts such as those with stable ischemic heart disease (SIHD) or when the comparison strategy is UFH monotherapy. Accordingly, the objective of the present study was to evaluate the use of bivalirudin when compared with UFH monotherapy in patients with NSTE-ACSs and in those with SIHD.
Methods
The patient population was derived from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry, the design, methods, and results of which have been described previously. 10 The registry was designed to prospectively assess the contemporary practice of PCI at >50 centers in the United States. A total of 10 144 patients were enrolled in waves 1 through 4 between July 2004 and June 2007. The institutional review board at each participating institution approved the study protocol, and written informed consent was obtained from all patients before participation in the registry.
Study Population
Patients with NSTE-ACSs or SIHD and treated with either UFH monotherapy or bivalirudin monotherapy as antithrombotic therapy during PCI were eligible for this analysis. The choice of antithrombotic strategy was left to the discretion of the physician performing the PCI.
Data Collection and Follow-Up
Patient data were collected prospectively on standardized case report forms and submitted to the data coordinating center (Harvard Clinical Research Institute, Boston, MA). For the purposes of this analysis, adequate clopidogrel loading before PCI was defined as either chronic clopidogrel therapy >1 week before PCI or a loading dose of ≥300 mg ≥6 hours before PCI or ≥600 mg ≥2 hours before PCI. By protocol, troponin, creatinine kinase, and creatinine kinase-MB levels were assessed at baseline (within 1 hour before the procedure) and every 8 hours for a minimum of 2 samples after the procedure and assayed using the clinical laboratory and reference values for each site. If an myocardial infarction (MI) was suspected clinically at a later point, additional biomarkers were obtained as clinically indicated.
Patients were contacted by telephone at 6 and 12 months after the index PCI. Events ascertained at follow-up included death, MI, stent thrombosis, and revascularization.
Outcomes
The primary outcome for this analysis was in-hospital composite bleeding, defined as clinically important access site bleeding, thrombolysis in myocardial infarction major or minor bleeding, or transfusion. 10 The primary ischemic outcome was death or MI, occurring in hospital. The secondary ischemic outcome was a composite of death, MI, or any unplanned repeat revascularization at 12 months. Other outcomes included individual rates of death, MI, unplanned repeat revascularization, and Academic Research Consortium-defined 11 definite or probable stent thrombosis both in hospital and at 12 months. All clinical outcomes were adjudicated by 2 cardiologists blinded to baseline variables.
Statistical Analyses
All analyses were performed using SPSS for Windows, version 16.0 (SPSS Inc, Chicago, IL) and SAS 9.3. Continuous variables are reported as mean value±SD or median and interquartile range (for non-normally distributed variables). Variables were compared across groups using Student t test (for normally distributed variables) or the Wilcoxon rank-sum test (for other variables) for continuous variables and χ 2 test or Fisher exact tests for categorical variables.
Propensity Score Matching
Analyses were performed separately for the NSTE-ACS and the SIHD cohort, after dividing the cohort into 2 groups based on the anticoagulation strategy at the time of index PCI: UFH monotherapy versus bivalirudin monotherapy. Given the differences in baseline characteristics between the 2 groups, we used propensity score matching to assemble a cohort for each comparison (separately for NSTE-ACS and SIHD cohorts) in which all the measured baseline covariates would be well balanced across the 2 groups. The propensity score is the conditional probability of having a particular exposure (bivalirudin use) given a set of measured baseline covariates 12, 13 and was estimated using a nonparsimonious multivariable logistic regression model, 14 using bivalirudin use as the dependent variable, and all 89 baseline characteristics displayed in Table 1 as covariates. Matching was performed using a greedy matching protocol (1:1 matching without replacement) with a caliper width of 0.6 of the SD. We estimated standardized differences for all 89 covariates before and after matching to assess prematch imbalance and postmatch balance. 15 Standardized differences <10% for a given covariate indicate a relatively small imbalance. 15 Analysis was performed to evaluate the risk of outcomes in the matched cohort. A multivariable model was then used to adjust for baseline differences in the matched cohort. A P value <0.05 was considered statistically significant.
Results
Among the patients in EVENT presenting with STEMI (n=737), those who received low-molecular-weight heparin (n=4), glycoprotein inhibitors (with either UFH [n=2736] or bivalirudin [n=471]) were excluded, leaving a cohort of 1480 patients with NSTE-ACSs and 3517 patients with SIHD who fulfilled the inclusion criteria for this study.
WHAT IS KNOWN
• Bivalirudin during percutaneous coronary intervention is associated with lower bleeding when compared with heparin plus glycoprotein IIb/IIIa inhibitor and in higher risk cohorts such as those with ST-segment-elevation myocardial infarction in randomized controlled trials.
• The use of bivalirudin versus unfractionated heparin monotherapy in patients without ST-segmentelevation myocardial infarction is not well defined.
WHAT THE STUDY ADDS
• In a real-world cohort of patients, use of bivalirudin during percutaneous coronary intervention was associated with a significant reduction in the risk of bleeding without a significant increase in ischemic outcomes, including stent thrombosis, when compared with unfractionated heparin monotherapy, either in patients with stable ischemic heart disease or non-ST-segment-elevation acute coronary syndromes.
• These associations should be tested in future randomized controlled trials. 
NSTE-ACS Cohort: Baseline Characteristics
Among the 1480 patients with NSTE-ACSs, 707 (48%) patients received UFH, and the rest received bivalirudin. Before propensity score matching, there were considerable differences between the UFH and the bivalirudin groups (Table 1) . After propensity score matching, the sample consisted of 518 patients in each treatment group (73% of original UFH group and 67% of the original bivalirudin group; Table 1 ). Within the matched population, the baseline characteristics were relatively well balanced between the 2 groups with absolute standardized differences <10% for most variables with the exception of New York Heart Association III/IV and Canadian Cardiovascular Society III symptoms, each of which were more common in the bivalirudin group than the UFH group. Overall, 52% of patients received an adequate clopidogrel load before PCI, and virtually all patients received a stent, the majority of which were drug eluting.
NSTE-ACS Cohort: Outcomes
In the matched cohort, there was no difference in the incidence of angiographic complications between the UFH and the bivalirudin groups ( Table 2 ). For the bleeding outcome, bivalirudin was associated with a 55% reduction in composite bleeding (difference, −3.3% [−0.8% to −5.8%]; P=0.01; number need to 
SIHD Cohort: Baseline Characteristics
Among the 3517 patients with SIHD, 1126 patients received UFH and the rest bivalirudin. Before propensity score matching, there were considerable differences between the UFH and the bivalirudin groups (Table 3 ). After propensity score matching, the sample consisted of 1031 patients in each treatment group (92% of the original UFH group and 43% of the original bivalirudin group; Table 3 ). After matching, baseline characteristics were well balanced between the 2 groups with absolute standardized differences <10% for all variables except Canadian Cardiovascular Society class III angina, which was less prevalent in the bivalirudin group (Table 3) . Overall, 50% of patients received adequate clopidogrel loading before PCI, and virtually all patients received a stent, the majority of which were drug eluting ( Table 3 ).
SIHD Cohort: Outcomes
In the matched cohort, there was no difference in the incidence of angiographic complications between the UFH and the bivalirudin groups ( (Table 4 ). For the secondary ischemic outcome, there was no significant difference between the groups (difference, −0.3% [2.7% to −3.3%]; P=0.86; Table 4 ), and results were similar after adjusting for baseline differences (adjusted RR=0.99; 95% CI, 0.88-1.11; P=0.82). There were no significant differences in the individual 12-month outcomes of death, MI, or stent thrombosis (difference, 0.0% [0.7% to −0.7%]; P=1.00) between the 2 groups as well (Table 4 ).
Discussion
The results of the present study, based on data derived from a registry of unselected patients undergoing PCI, showed a significant reduction in bleeding with bivalirudin when compared with UFH monotherapy in both the NSTE-ACS and the SIHD cohort. These results suggest that treatment of 30 patients with NSTE-ACSs or 53 patients with SIHD with bivalirudin will prevent 1 bleeding event, with no statistically significant increase in the risk of ischemic complications including stent thrombosis, when compared with UFH monotherapy.
Bivalirudin for NSTE-ACSs
The efficacy and safety of bivalirudin has been tested in many randomized trials of patients with NSTE-ACSs. In the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial of patients with NSTE-ACSs, bivalirudin monotherapy was noninferior to heparin+GPI for the composite ischemic outcome (death, MI, or unplanned revascularization for ischemia) and reduced the risk of ACUITY major bleeding and net clinical outcome at 30 days. 7 Similarly, in the Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia Among Anti-Platelet and Anti-Thrombotic Agents-Thrombolysis in Myocardial Infarction-30 (PROTECT-TIMI-30) of patients with NSTE-ACSs, bivalirudin monotherapy was associated with reduced thrombolysis in myocardial infarction minor bleeding and transfusion when compared with heparin+GPI. 16 However, neither of these trials compared bivalirudin versus heparin monotherapy. Our study thus extends the observation from these randomized trials to a cohort of patients treated with heparin monotherapy and shows that the bleeding advantage of bivalirudin is preserved even when compared with heparin monotherapy. Moreover, there was no statistically significant increase in the risk of either 30-day or 12-month ischemic outcomes with use of bivalirudin. It is reassuring that the risk of Academic Research Consortium-defined stent thrombosis was low and similar between the 2 groups. Of note, although there was no statistically significant increase in the risk of ischemic outcomes with bivalirudin, the CIs around the event rate do not rule out a small increase, and the study is likely underpowered to detect this small increase.
Bivalirudin for SIHD
The efficacy and safety of bivalirudin during PCI in patients without acute coronary syndromes is less well defined-particularly when compared with UFH alone. In the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial of 6010 patients undergoing urgent or elective PCI, bivalirudin was associated with significant reduction in major bleeding without any difference in the composite of death, MI, or urgent repeat revascularization when compared with UFH+GPI. In the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 3) trial of 4570 patients with stable or unstable angina, bivalirudin was associated with significant reduction in the risk of major bleeding (44% reduction) when compared with UFH monotherapy, with no difference in the composite of death, MI, or urgent target-vessel revascularization. 17 Our results showing a 50% reduction in composite bleeding with bivalirudin are therefore concordant with the above results. Moreover, there was no significant difference in ischemic outcomes including stent thrombosis between the 2 groups, although the CI around these estimates does not rule out the possibility of a small increase with bivalirudin.
Previous studies and analyses have established an association between bleeding and intermediate-term mortality. [1] [2] [3] [4] In our study, despite reduced bleeding with bivalirudin versus UFH monotherapy in both the NSTE-ACS cohort and the SIHD cohort, there was no significant difference in 1-year mortality between the 2 treatment groups. The 1-year mortality rate was numerically lower in the bivalirudin group in both the NSTE-ACS cohort (4.1% versus 4.6%) and the SIHD cohort (2.8% versus 3.1%), although these differences were not statistically significant. Our study was not powered to show a difference in mortality, and larger studies are needed to test these associations. In addition, although there was no statistically significant difference between bivalirudin and UFH monotherapy for ischemic outcomes, the upper limit of the 95% CI does not rule out a clinically meaningful increase in either the primary ischemic outcome (NSTE-ACS 95% CI, 0.85-1.41; SIHD 95% CI, 0.85-1.25) or the secondary ischemic outcome (NSTE-ACS 95% CI, 0.94-1.26; SIHD 95% CI, 0.88-1.11) with bivalirudin.
In our previous study from EVENT, we have shown that use of bivalirudin use during PCI was associated with a lower risk of bleeding at all comparator-activated clotting time levels without an increase in ischemic outcomes demonstrating the efficacy of bivalirudin at reducing bleeding even when compared with low dose of UFH. 18 Taken together with the current study, there are thus consistent data suggesting reduced bleeding with bivalirudin in patients with STEMI, NSTE-ACSs, or SIHD and when compared with UFH+GPI or UFH monotherapy and across various comparator activated clotting time levels. The association between bivalirudin and ischemic outcomes, however, needed to be explored in larger trials.
Study Limitations
Our study uses data derived from a registry with prospective follow-up of patients and hence should be regarded as hypothesis generating. Given that the treatment allocation was not randomized, we used propensity score matching to adjust for selection bias. Despite this rigorous approach, we cannot exclude the possibility that our results were influenced by residual confounding. In addition, the follow-up duration was relatively short and differences in mortality related to bleeding event may emerge on longer term follow-up. Moreover, we did not use the recently updated universal definition of MI or the Bleeding Academic Research Consortium definition of bleeding because the EVENT registry was designed several years before those standards were established. Although patients with STEMI who did not receive a GPI is an interesting cohort to evaluate, the proportion of patients who did not receive a GPI was small, making any reasonable comparison between heparin and bivalirudin underpowered. In addition, the results are applicable in the context of clopidogrel use alone, and it cannot be generalizable to cohorts treated with novel P2Y12 inhibitors.
Conclusions
In a real-world cohort of patients undergoing PCI using contemporary devices, procedures, and pharmacotherapy, use of bivalirudin during PCI was associated with a significant reduction in the risk of bleeding without a significant increase in ischemic outcomes, including stent thrombosis, when compared with UFH monotherapy, in either patients with SIHD or patients with NSTE-ACSs. These associations should be tested in future randomized controlled trials.
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